Prognostic value of early haemodynamic valve deterioration after TAVI

Antonin Trimaille¹, MD, PhD; Olivier Morel², MD, PhD; Alberto Alperi³, MD, PhD; Gabriela Veiga-Fernandez⁴, MD; Luis Nombela-Franco⁵, MD; Victoria Vilalta⁶, MD, PhD; Antonio Munoz-Garcia⁷, MD; Jorge Nuche⁸, MD, PhD; Anna Franzone⁹, MD, PhD; Marina Urena¹⁰, MD, PhD; Lluis Asmarats¹¹, MD; Ander Regueiro¹², MD; Maria del Trigo¹³, MD; Vincent Auffret¹⁴, MD; David del Val¹⁵, MD; Vicenç Serra¹⁶, MD; Adrien Carmona², MD; Pablo Avanzas³, MD, PhD; Victor Fradejas-Sastre⁴, MD; Ivan Sanchez⁵, MD; Michele Trichilo⁶, MD; Nicolas Maneiro⁸, MD; Maddalena Immobile Molaro⁹, MD; Quentin Fischer¹⁰, MD; Dabit Arzamendi¹¹, MD; Eduardo Flores-Umanzor¹², MD; Juan Francisco Oteo¹³, MD; Maxime Nolf¹⁴, MD; Fernando Alfonso¹⁵, MD; Pedro Díaz Pockels¹⁶, MD; Camil Elkadiri¹, MS; Pedro Cepas-Guillén¹^,¹², MD, PhD; Marisa Avvedimento¹, MD; Josep Rodés-Cabau¹^,¹², MD, PhD

Abstract

Background: Early haemodynamic valve deterioration (HVD) was associated with worse clinical outcomes and bioprosthetic durability after transcatheter aortic valve implantation (TAVI) in a single-centre study.

Aims: The aim of this study was to evaluate the incidence, predictors, and prognostic impact of early HVD in a large-scale TAVI population.

Methods: We analysed the data from an international, multicentre registry including consecutive patients from 16 centres undergoing TAVI. Early HVD was defined as an increase of at least 10 mmHg in the mean transaortic gradient on echocardiography performed within the first three months after TAVI, compared with the discharge echocardiography. The primary endpoint was the valve-related long-term clinical efficacy according to the Valve Academic Research Consortium 3.

Results: Among 7,392 patients, early HVD was observed in 231 patients (3.1%). Body mass index (adjusted odds ratio [aOR] per 5 kg/m² increase 1.15, 95% confidence interval [CI]: 1.02-1.30), prosthesis size <26 mm (aOR 1.96, 95% CI: 1.43-2.70), valve-in-valve procedure (aOR 2.76, 95% CI: 1.83-4.08), and the absence of anticoagulation at discharge (aOR 1.64, 95% CI: 1.22-2.22) were independent predictors of early HVD. After a median follow-up of 4 years (interquartile range 2-5), early HVD was independently associated with a lower valve-related long-term clinical efficacy (subdistribution hazard ratio [sHR] 0.42, 95% CI: 0.32-0.56), and a higher risk of stroke (sHR 2.32, 95% CI: 1.51-3.57), stage 2 or 3 (sHR 2.74, 95% CI: 2.10-3.57) or stage 3 bioprosthetic valve dysfunction (sHR 3.53, 95% CI: 2.15-5.79), and bioprosthetic valve failure (sHR 3.04, 95% CI: 2.06-4.52). Consistent findings were observed in a propensity score-matched cohort and in different sensitivity analyses.

Conclusions: Early HVD was observed in 3.1% of patients and was associated with adverse clinical and haemodynamic outcomes after TAVI. These findings validate the clinical relevance of detecting early HVD and the necessity for further research to guide optimal management of these patients.

Forgot your password?

No account yet?
Sign up for free!

Create my pcr account

Join us for free and access thousands of articles from EuroIntervention, as well as presentations, videos, cases from PCRonline.com

Coronary interventions Interventions for valvular disease Interventions for heart failure Peripheral interventions Interventions for hypertension Interventions for stroke STEMI NSTEMI Stable CAD Stents and scaffolds Left main and multivessel disease Bifurcation lesions CTO TAVI Mitral valve replacement and repair Tricuspid / Pulmonary valve Acute heart failure Chronic heart failure Below the knee AAA Iliac / Femoral / Popliteal Renal artery angioplasty Renal denervation Carotid stenting LAA closure Ischaemic stroke

stroke transcatheter aortic valve implantation bioprosthetic valve failure haemodynamic valve deterioration leaflet thrombosis

Volume 22 Number 11

Jun 1, 2026